Thursday, June 24, 2021 7:54:46 PM
Another clinical trial of 1
My cousin has dermatomyositis- her immune system is attacking her muscle and skin. She takes prednisone, hydroxychloroquin, methotrexate, imuran - you name it to suppress her immune system. For the last 5 years I have been telling her to take EPA and she finally started OmegaVia EPA 500 at 4gm/day about 5 months ago. Today she texted me in a panic - the Canadian supplier of OmegaVia is out of stock and has been for a while and she desperately looking for another source. She tried to get her rheumatologist to prescribe V but she wouldn’t (no evidence, and she is right). My cousin said she is doing the best she has ever felt in 5 years since starting EPA, her prednisone dose is down to only 2mg/day (lowest previously was 10mg) and her CK levels are normal. Rheumatologist still won’t prescribe V.
One more example of how V (or at least a cheap imitation of V) restores balance to the immune system. Autoimmune diseases are a whole new category of therapies. Therapies that won’t be researched without patents being able to protect the investment. Sad.
My cousin has dermatomyositis- her immune system is attacking her muscle and skin. She takes prednisone, hydroxychloroquin, methotrexate, imuran - you name it to suppress her immune system. For the last 5 years I have been telling her to take EPA and she finally started OmegaVia EPA 500 at 4gm/day about 5 months ago. Today she texted me in a panic - the Canadian supplier of OmegaVia is out of stock and has been for a while and she desperately looking for another source. She tried to get her rheumatologist to prescribe V but she wouldn’t (no evidence, and she is right). My cousin said she is doing the best she has ever felt in 5 years since starting EPA, her prednisone dose is down to only 2mg/day (lowest previously was 10mg) and her CK levels are normal. Rheumatologist still won’t prescribe V.
One more example of how V (or at least a cheap imitation of V) restores balance to the immune system. Autoimmune diseases are a whole new category of therapies. Therapies that won’t be researched without patents being able to protect the investment. Sad.
Recent AMRN News
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:04 AM
- Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization • GlobeNewswire Inc. • 01/09/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2026 12:05:27 PM
- Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities • GlobeNewswire Inc. • 01/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:10 PM
